Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm

The outburst of inflammatory response and hypercoagulability are among the factors contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a xanthine-derived drug registered for the treatment of vascular claudication, has been reported to display broad-spectrum anti-infla...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wiktoria Feret, Magdalena Nalewajska, Łukasz Wojczyński, Wojciech Witkiewicz, Patrycja Kłos, Violetta Dziedziejko, Andrzej Pawlik
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 SARS-CoV-2 cytokine storm cytokines pentoxifylline pneumonia Medicine R
Acceso en línea:	https://doaj.org/article/cf4240f217e4421e845f64298641d07c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf4240f217e4421e845f64298641d07c
record_format	dspace
spelling	oai:doaj.org-article:cf4240f217e4421e845f64298641d07c2021-11-25T18:01:35ZPentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm10.3390/jcm102253052077-0383https://doaj.org/article/cf4240f217e4421e845f64298641d07c2021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5305https://doaj.org/toc/2077-0383The outburst of inflammatory response and hypercoagulability are among the factors contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a xanthine-derived drug registered for the treatment of vascular claudication, has been reported to display broad-spectrum anti-inflammatory and immunomodulatory properties via adenosine A2A receptor (A2AR)-related mechanisms, in parallel to its rheological actions. Prior studies have indicated the efficacy of PTX in the treatment of various pulmonary diseases, including the management of acute respiratory distress syndrome of infectious causes. Therefore, PTX has been proposed to have potential benefits in the treatment of SARS-CoV-2 symptoms, as well as its complications. The aim of this review is to discuss available knowledge regarding the role of PTX as a complementary therapeutic in SARS-CoV-2.Wiktoria FeretMagdalena NalewajskaŁukasz WojczyńskiWojciech WitkiewiczPatrycja KłosVioletta DziedziejkoAndrzej PawlikMDPI AGarticleCOVID-19SARS-CoV-2cytokine stormcytokinespentoxifyllinepneumoniaMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5305, p 5305 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 SARS-CoV-2 cytokine storm cytokines pentoxifylline pneumonia Medicine R
spellingShingle	COVID-19 SARS-CoV-2 cytokine storm cytokines pentoxifylline pneumonia Medicine R Wiktoria Feret Magdalena Nalewajska Łukasz Wojczyński Wojciech Witkiewicz Patrycja Kłos Violetta Dziedziejko Andrzej Pawlik Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
description	The outburst of inflammatory response and hypercoagulability are among the factors contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a xanthine-derived drug registered for the treatment of vascular claudication, has been reported to display broad-spectrum anti-inflammatory and immunomodulatory properties via adenosine A2A receptor (A2AR)-related mechanisms, in parallel to its rheological actions. Prior studies have indicated the efficacy of PTX in the treatment of various pulmonary diseases, including the management of acute respiratory distress syndrome of infectious causes. Therefore, PTX has been proposed to have potential benefits in the treatment of SARS-CoV-2 symptoms, as well as its complications. The aim of this review is to discuss available knowledge regarding the role of PTX as a complementary therapeutic in SARS-CoV-2.
format	article
author	Wiktoria Feret Magdalena Nalewajska Łukasz Wojczyński Wojciech Witkiewicz Patrycja Kłos Violetta Dziedziejko Andrzej Pawlik
author_facet	Wiktoria Feret Magdalena Nalewajska Łukasz Wojczyński Wojciech Witkiewicz Patrycja Kłos Violetta Dziedziejko Andrzej Pawlik
author_sort	Wiktoria Feret
title	Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
title_short	Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
title_full	Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
title_fullStr	Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
title_full_unstemmed	Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
title_sort	pentoxifylline as a potential adjuvant therapy for covid-19: impeding the burden of the cytokine storm
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/cf4240f217e4421e845f64298641d07c
work_keys_str_mv	AT wiktoriaferet pentoxifyllineasapotentialadjuvanttherapyforcovid19impedingtheburdenofthecytokinestorm AT magdalenanalewajska pentoxifyllineasapotentialadjuvanttherapyforcovid19impedingtheburdenofthecytokinestorm AT łukaszwojczynski pentoxifyllineasapotentialadjuvanttherapyforcovid19impedingtheburdenofthecytokinestorm AT wojciechwitkiewicz pentoxifyllineasapotentialadjuvanttherapyforcovid19impedingtheburdenofthecytokinestorm AT patrycjakłos pentoxifyllineasapotentialadjuvanttherapyforcovid19impedingtheburdenofthecytokinestorm AT violettadziedziejko pentoxifyllineasapotentialadjuvanttherapyforcovid19impedingtheburdenofthecytokinestorm AT andrzejpawlik pentoxifyllineasapotentialadjuvanttherapyforcovid19impedingtheburdenofthecytokinestorm
_version_	1718411770258784256

Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm

Ejemplares similares